Perhaps in support of this is the differential frequency of PDGFRA and CCND2 amplifications in tumors identified as GBM versus a primitive neuroectodermal tumor (PNET) in a series reported by Korshunov et al. [77]. This evidence concerns the gene PDGFRA and primitive neuroectodermal tumor.